CABOLONG 40 MG

Introduction to CABOLONG 40 mg

CABOLONG 40 mg is a pharmaceutical medication that contains cabozantinib as its active ingredient. Cabozantinib is a tyrosine kinase inhibitor (TKI) that works by targeting and inhibiting specific proteins involved in the growth and spread of cancer cells. It is primarily used in the treatment of certain types of cancers, particularly advanced kidney cancer (renal cell carcinoma), liver cancer (hepatocellular carcinoma), and thyroid cancer.

What is CABOLONG?

Cabolong (Cabozantinib) is a brand name for the medication Cabozantinib, which is an oral tyrosine kinase inhibitor (TKI). It is a type of targeted therapy used to treat various types of cancer.

Cabozantinib works by inhibiting the activity of multiple receptor tyrosine kinases, including RET, MET, and VEGFR2. These kinases help cancer cells grow and proliferate. By blocking their activity, Cabozantinib helps to slow down or stop the growth of cancer cells.

Indication for Use Cabolong 40 mg:

Cabolong 40mg is designed to treat the following specific health conditions:

Renal Cell Carcinoma (RCC): Cabozantinib 40mg is indicated for the treatment of advanced renal cell carcinoma, a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a section of the kidney's tiny tubes that carry waste products from the blood to the urine.

Hepatocellular Carcinoma (HCC): Cabozantinib 40mg is indicated for the treatment of advanced hepatocellular carcinoma, a type of liver cancer that originates in the main type of liver cell (hepatocyte).

Medullary Thyroid Carcinoma (MTC): Cabozantinib 40mg is indicated for the treatment of progressive, metastatic medullary thyroid carcinoma, a type of thyroid cancer that originates in the parafollicular cells (also known as C cells) of the thyroid gland.

Composition of CABOLONG 40 mg

Cabolong 40mg works by targeting specific receptors and pathways in the body to slow down or stop the growth of cancer cells.

Tyrosine Kinase Inhibition:

The active ingredient, Cabozantinib, is a tyrosine kinase inhibitor (TKI). It works by inhibiting the activity of multiple receptor tyrosine kinases, including:

RET (Rearranged during Transfection): Cabozantinib inhibits the activity of RET, a receptor tyrosine kinase involved in the growth and proliferation of cancer cells.

MET (Mesenchymal-Epithelial Transition factor): Cabozantinib inhibits the activity of MET, a receptor tyrosine kinase involved in the growth and proliferation of cancer cells.

VEGFR2 (Vascular Endothelial Growth Factor Receptor 2): Cabozantinib inhibits the activity of VEGFR2, a receptor tyrosine kinase involved in angiogenesis (the formation of new blood vessels).

Inhibition of Cancer Cell Growth and Proliferation:

By inhibiting the activity of these receptor tyrosine kinases, Cabozantinib reduces the growth and proliferation of cancer cells. This leads to a decrease in tumor size and a reduction in the spread of cancer cells.

Anti-Angiogenic Effects:

Cabolong 40mg also has anti-angiogenic effects, which means it inhibits the formation of new blood vessels that supply oxygen and nutrients to cancer cells. This reduces the growth and proliferation of cancer cells.

Mechanism of Action

Overall Mechanism of Action:

The mechanism of action of Cabolong 40mg involves the inhibition of multiple receptor tyrosine kinases, leading to a decrease in cancer cell growth and proliferation, as well as anti-angiogenic effects. This results in a reduction in tumor size and a decrease in the spread of cancer cells.

Dosage and Administration

The recommended dosage of Cabolong 40mg varies depending on the specific condition being treated.

Renal Cell Carcinoma (RCC):

The recommended dosage of Cabolong 40mg for the treatment of advanced RCC is 60mg once daily.

Hepatocellular Carcinoma (HCC):

The recommended dosage of Cabolong 40mg for the treatment of advanced HCC is 60mg once daily.

Medullary Thyroid Carcinoma (MTC):

The recommended dosage of Cabolong 40mg for the treatment of progressive, metastatic MTC is 140mg once daily.

Dosage Modifications:

• In patients with severe hepatic impairment, the recommended dosage of Cabolong 40mg is 20mg once daily.
• In patients with diarrhea, the dosage may need to be reduced to 40mg once daily.
• In patients with palmar-plantar erythrodysesthesia (hand-foot syndrome), the dosage may need to be reduced to 40mg once daily.

Administration:

• Cabolong 40mg tablets should be taken orally, with or without food.
• The tablets must be taken whole; they must not be chewed, crushed, or broken.
• Patients should be advised to take the medication at the same time every day.

Side Effects of Cabolong (Cabozantinib) 40 mg:

• Fatigue
• Diarrhea
• Nausea
• Vomiting
• Stomatitis
• Hypertension
• Decreased appetite
• Taste changes
• Palmar-plantar erythrodysesthesia

Warnings and Precautions

Cabolong 40mg is a prescription medication that should be used with caution due to the potential for serious side effects and interactions.

Warnings:

Hypertension: Cabolong 40 mg can cause hypertension, which can lead to serious cardiovascular events. Blood pressure should be monitored regularly, and antihypertensive therapy should be initiated or adjusted as necessary.

Gastrointestinal Perforation: Cabolong 40 mg can cause gastrointestinal perforation, which can be fatal. Patients should be monitored for signs and symptoms of gastrointestinal perforation, such as severe abdominal pain, vomiting, and fever.

Hemorrhage: Cabolong 40mg can cause hemorrhage, which can be fatal. Patients should be monitored for signs and symptoms of hemorrhage, such as bleeding, bruising, and petechiae.

Thrombotic Events: Cabolong 40 mg can cause thrombotic events, such as heart attack and stroke. Patients should be monitored for signs and symptoms of thrombotic events, such as chest pain, shortness of breath, and weakness or numbness in the face, arm, or leg.

Wound Healing Complications: Cabolong 40mg can cause wound healing complications, such as wound dehiscence and wound infection. Patients should be monitored for signs and symptoms of wound healing complications, such as wound pain, swelling, and redness.

Precautions:

Pregnancy and Lactation: Cabolong 40mg can cause fetal harm and is not recommended for use during pregnancy or lactation.

Hepatic Impairment: Cabolong 40mg should be used with caution in patients with hepatic impairment, as it can cause hepatotoxicity.

Renal Impairment: Cabolong 40mg should be used with caution in patients with renal impairment, as it can cause nephrotoxicity.

Drug Interactions: Cabolong 40mg can interact with other medications, such as warfarin, and can cause adverse reactions.

Monitor for Adverse Reactions: Patients should be monitored regularly for adverse reactions, such as diarrhea, palmar-plantar erythrodysesthesia, and hypertension.

Conclusion:

Cabolong 40mg is a prescription medication that contains the active ingredient Cabozantinib, a tyrosine kinase inhibitor used to treat various types of cancer. It works by inhibiting cancer cell growth and proliferation and is available in a 40mg tablet form. Patients should follow the recommended dosage and administration instructions carefully to minimize the risk of adverse reactions and ensure optimal treatment outcomes.